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Abstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central 
nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) 
products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b 
subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-
modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 
2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog 
that preferentially depletes lymphocyte subpopulations. This sustained effect on lymphocytes 
is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), 
a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and 
risk of disability progression in comparison with placebo. Cladribine was well tolerated in the 
study, with the most common adverse effects being headache, nausea, upper respiratory tract 
infections, and lymphocytopenia. An ongoing study is evaluating the efficacy and safety of the 
combination of oral cladribine and IFN-β products. A further ongoing study is examining the 
use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although 
the results of CLARITY are promising, the exact role of oral cladribine may be better defined 
with the completion of ongoing studies.
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Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous 
system. More than 400,000 Americans and 2.7 million people worldwide have been 
diagnosed with MS.1 MS more commonly affects women by a ratio of 2:1 over men, 
and 80% of patients will be diagnosed at 16–45 years of age.1 The clinical course of 
MS varies between patients, is characterized by relapses and remissions, and may be 
categorized on the basis of the pattern of these episodes. The clinical categories of MS 
include progressive relapsing (PRMS) and relapsing-remitting (RRMS), which may 
eventually become chronic and progressive MS. Chronic and progressive MS can be 
further subdivided into secondary progressive MS and primary progressive MS.2
Currently, interferon (IFN) β-1a intramuscularly (Avonex®), IFN β-1a subcutane-
ously (Rebif®), IFN β-1b subcutaneously (Betaseron®), glatiramer acetate (Copaxone®), 
natalizumab (Tysabri®), and mitoxantrone (Novantrone®) are approved disease-
modifying therapies (DMTs) for the treatment of RRMS. The immunomodulatory 
interferons (IFNs) and glatiramer, are considered first-line agents, whereas natalizumab, 
an immunosuppressive agent, is considered second-line. Mitoxantrone is indicated for 





be used early in the course of disease due to its toxicity profile 
(ie, cardiotoxicity,   leukemia), delaying treatment should be 
avoided because of the risk of clinical deterioration.3
Three trials have demonstrated the efficacy of the IFNs 
in comparison with placebo. The IFNB Multiple Sclerosis 
Study Group compared 1.6 MIU of IFN β-1b, 8 MIU of 
IFN β-1b, and placebo administered subcutaneously every 
other day.4 Annual relapse rates were 1.17 (P = 0.01 ver-
sus placebo), 0.84 (P = 0.0001 versus placebo), and 1.27, 
  respectively. The percentage of subjects who were relapse-free 
after two years was 18.4%, 29% (P = 0.007 versus placebo), 
and 14.6%, respectively. For RRMS subjects who received 
IFN β-1a subcutaneously three times weekly, the PRISMS 
(Prevention of Relapses and Disability by Interferon beta-1a 
Subcutaneously in Multiple Sclerosis) study group found 
both a decreased frequency of relapses over two years (risk 
reductions 27%, 95% confidence interval [CI]: 14%–39% 
and 33%, 95% CI: 21%–44%, for the 22 µg and 44 µg 
groups, respectively) and a delayed accumulation of physical 
disability.5 The burden of disease, measured with magnetic 
resonance imaging, showed a progressive increase of 10.9%, 
a 1.2% decrease, and a 3.8% decrease for the placebo, 22 µg, 
and 44 µg groups, respectively (P , 0.0001 compared with 
placebo for both doses). The CHAMPS (Controlled High 
Risk Avonex Multiple Sclerosis Study) investigators found 
a relative reduction in brain lesion volume at 18 months in 
subjects with an acute demyelinating event who received 30 
µg of IFN β-1a intramuscularly weekly (P , 0.001).6 The 
cumulative probability of subjects developing clinically 
definite MS over a three-year follow-up period was lower in 
the IFN β-1a group compared with placebo (0.56, 95% CI: 
0.38–0.81, P = 0.002).
A few studies have attempted to determine the impact of 
varying IFN dosage regimens on RRMS. The EVIDENCE 
(Evidence for Interferon Dose-Response: European-North 
American Comparative Efficacy) trial demonstrated that after 
24 weeks 74.9% of subjects receiving IFN β-1a 44 µg subcu-
taneously three times weekly were relapse-free versus 63.3% 
of subjects who received IFN β-1a 30 µg intramuscularly 
once weekly.7 The INCOMIN (Independent Comparison of 
Interferon) trial showed that after two years 51% of subjects 
receiving IFN β-1b 250 µg subcutaneously every other day 
remained relapse-free versus 36% of subjects receiving IFN 
β-1a 30 µg intramuscularly once weekly.8 These data   suggest 
that IFN β products may be more effective when dosed more 
frequently.
A pivotal, two-year, multicenter Phase III study has 
demonstrated that glatiramer, when administered as 20 mg 
subcutaneously daily, reduces relapse rates by 29% compared 
with placebo (P = 0.007).9
A few studies have compared the efficacy of the IFN 
products with that of glatiramer, including the BEYOND 
(Betaferon Efficacy Yielding Outcomes of a New Dose) and 
REGARD (Rebif vs Glatiramer Acetate in Relapsing MS 
Disease) trials. The three arms of the BEYOND trial included 
IFN β-1b 250 µg subcutaneously every other day, IFN β-1b 
500 µg subcutaneously every other day, and glatiramer 20 mg 
subcutaneously daily.10 The BEYOND trial demonstrated no 
difference in annual relapse rate between glatiramer and the 
250 µg IFN β-1b dose (hazards ratio [HR] 1.06, 95% CI: 
0.89–1.26, P = 0.73) and the 500 µg IFN β-1b dose (HR 
0.98, 95% CI: 0.82–1.18, P = 0.43). The REGARD trial 
compared IFN β-1a 44 µg subcutaneously three times weekly 
with glatiramer 20 mg subcutaneously daily.11 The REGARD 
trial demonstrated no difference in time to first relapse (HR 
0.94, 95% CI: 0.74–1.21, P = 0.64). Because of their similar 
efficacy, any of these agents may be considered first-line for 
the treatment of RRMS.
Natalizumab was first approved for the treatment of 
RRMS based on the findings of two studies. Natalizumab 
reduced the relapse rate at one year by 68% versus placebo 
(P , 0.001) in the AFFIRM (Natalizumab Safety and 
  Efficacy in Relapsing Remitting Multiple Sclerosis) study.12 
The   SENTINEL (Safety and Efficacy of Natalizumab 
in Combination with Interferon Beta-1a in Patients with 
Relapsing Remitting Multiple Sclerosis) study compared 
combination treatment with IFN β-1a plus natalizumab with 
IFN β-1a monotherapy.13 Combination therapy resulted in 
a 24% reduction in the relative risk of sustained disability 
progression (P = 0.02). Combination therapy was also 
associated with a lower annual relapse rate (34% versus 
75%, P , 0.001). While natalizumab is effective for active 
forms of RRMS, it is usually reserved for patients who 
have inadequate responses to or are unable to tolerate first-
line DMTs, because of the risk of progressive multifocal 
leukoencephalopathy.14
While in the studies all of the DMTs for the treatment 
of RRMS have proven to be effective in decreasing relapse 
rates, increasing the percentage of patients that are relapse-
free, and/or delaying progression of disease, reports show that 
7%–49% of RRMS patients do not have an adequate response 
to DMT.15 The DMTs must be administered either subcuta-
neously or intramuscularly, and may lead to toxicities, such 
as flu-like symptoms, headache, or depression with the IFN 
products, injection reactions with glatiramer, and multifocal 




Oral cladribine for relapsing-remitting multiple sclerosis
to the need for the development of potentially better tolerated 
oral treatments, such as cladribine, for RRMS.
Pharmacology and 
pharmacokinetics
Cladribine, also known as 2-chlorodeoxyadenosine, is a 
  synthetic adenosine deaminase-resistant purine nucleoside ana-
log that preferentially depletes lymphocyte   subpopulations.16 
This beneficial and sustained effect on   lymphocytes is 
advantageous for patients with MS. Cladribine is   structurally 
similar to deoxyadenosine, with the substitution of a   chlorine 
atom for a hydrogen atom at the two position of the purine 
ring.17 Cladribine is a prodrug which requires passive intra-
cellular transport where phosphorylation to active metabo-
lites occurs. It is phosphorylated by deoxycytidine kinase 
to active triphosphate deoxynucleotide. Accumulation of 
active triphosphate deoxynucleotide results in disrupted 
cellular metabolism, DNA strand breaks, interference with 
DNA repair, and eventual cell death. Deoxyadenosine can be 
deaminated to deoxyinosine by adenosine deaminase. This 
enzyme regulates deoxyadenosine concentrations by control-
ling the deamination process. However, cladribine is resistant 
to the effects of adenosine deaminase.   Following cladribine 
administration, lymphocytes will accumulate high con-
centrations of deoxynucleotides. This accumulation is due 
to a high activity level of deoxycytidine kinase associated 
with lymphocytes.18 These characteristics of cladribine, 
including activation by deoxycytidine kinase and resistance 
to adenosine deaminase, combined with high concentrations 
of deoxycytidine kinase in lymphocytes, results in the unique 
preferential lymphocytotoxicity associated with cladribine. 
Also, cladribine may prevent the migration of monocytes and 
lymphocytes across the blood–brain barrier into the central 
nervous system. Cladribine has been shown to decrease the 
migratory capacity of CD14+ monocytes, CD4+ T lympho-
cytes, and CD8+ T lymphocytes, with greater effects on T 
lymphocytes.19
The pharmacokinetic properties of cladribine were investi-
gated using high-performance liquid chromatography to evalu-
ate two- and 24-hour 0.14 mg/kg infusions. The volume of 
distribution was determined to be 9.2 ± 5.4 L/kg. When using a 
two-compartment model, mean alpha and beta half-lives were 
35 minutes and 6.7 hours, respectively. The   concentration 
obtained 6.3 hours after the start of the two-hour infusion had 
decreased to the same as the steady-state concentration   during 
the 24-hour infusion. When using a three-compartment model, 
mean alpha, beta, and gamma half-lives were eight   minutes, 
one hour and six minutes, and 6.3 hours, respectively. The long 
gamma phase after the two-hour infusion suggests that 
cladribine could be administered intermittently with retained 
activity.20
Additional methods, including radioimmunoassay, have 
evaluated the pharmacokinetic properties of cladribine. 
The terminal half-life has been found to range from 5.7 to 
19.7 hours with a volume of distribution of 54 to 357 L/m2.21 
In patients with a healthy central nervous system, cladribine 
concentrations in cerebrospinal fluid are 25% that of plasma 
concentrations; however, in subjects with meningeal disease, 
cladribine concentrations in cerebrospinal fluid exceed 
plasma concentrations.21 The renal elimination of cladribine 
was evaluated in children with acute leukemia. Mean renal 
clearance as a percentage of total clearance was 51%, with 
a range from 11% to 85.1%.22
Oral cladribine dissolved in phosphate-buffered saline 
revealed a mean bioavailability of 48 ± 8% for subjects 
dosed with 0.14 mg/kg and 55 ± 17% for subjects dosed with 
0.28 mg/kg.23 The effects of food and proton pump inhibitors 
on oral cladribine administration have also been studied.24 
In this study, oral bioavailability was found to be 42% with 
food intake and 46% while fasting, although this difference 
was not statistically significant. However, food intake did 
reduce the maximum plasma concentration by 40% and 
delayed time to reach maximum plasma concentration by 
approximately 0.8 hours. Omeprazole did not significantly 
affect the bioavailability of oral cladribine. Bioavailability 
was 51% with omeprazole treatment and 46% without treat-
ment. Overall, oral cladribine can be taken without regard to 
omeprazole or food.
The mechanism of action and pharmacodynamic proper-
ties of cladribine make it unique. The preferential and sus-
tained effects on lymphocytes render cladribine a potential 
short-course treatment for MS. Cladribine’s long elimination 
half-life and acceptable bioavailability makes once-daily 
dosing of an oral formulation possible. Hence, cladribine has 
been formulated as a 10 mg tablet for oral administration. 
Clinical studies are necessary to determine if these pharmaco-
dynamic and pharmacokinetic properties can be successfully 
exploited for short-term oral treatment of MS.
Clinical studies
Giovannoni et al conducted CLARITY (CLAdRIbine Tablets 
Treating MS OrallY), a Phase III trial evaluating the safety and 
efficacy of oral cladribine in subjects with RRMS.25 A total of 
1326 subjects were randomized in this double-blind, placebo-
controlled, multicenter trial in a 1:1:1 ratio to receive cladribine 





administered as short courses. A course of treatment involved 
administration of study drugs once daily for the first four or 
five days of a 28-day period. Once-daily cladribine consisted of 
administration of one or two 10 mg tablets. Subjects received 
two courses of cladribine followed by two courses of placebo in 
the 3.5 mg/kg group, four courses of cladribine in the 5.25 mg/
kg group, or four courses of placebo during the first 48-week 
treatment period starting on day one and at weeks 5, 9, and 13. 
This resulted in patients taking cladribine tablets for 8–20 days 
during the first 48 weeks. Both cladribine groups received two 
courses of treatment during the second 48-week treatment 
period. Subjects in the placebo group also received two courses 
of placebo. This resulted in patients taking cladribine tablets for 
8–10 days during the second 48 weeks. If a subject had more 
than one relapse episode or a sustained increase in the Kurtke 
Expanded Disability Status Scale (EDSS), subcutaneous IFN 
β-1a could be used.
The primary endpoint assessed was rate of relapse at 
96 weeks. Investigators defined relapse as an increase of two 
points in at least one EDSS functional system or at least two 
functional systems with an increase of one point, which had 
to precede at least a month of clinical stability or improve-
ment, in the absence of a fever.
The secondary endpoints assessing efficacy were the pro-
portion of subjects that were relapse-free, time to sustained 
progression of disability, time to first relapse, and the propor-
tion of subjects receiving IFN β-1a rescue therapy. Sustained 
progression of disability was defined as a sustained increase 
of at least three months of at least one point in the EDSS score 
or an increase of 1.5 points if the baseline EDSS score was 
zero. The magnetic resonance imaging secondary endpoints 
included the mean number of lesions per subject per scan 
at 96 weeks for gadolinium-enhancing T1 weighted lesions, 
active T2 weighted lesions, and combined unique lesions. 
Unique lesions were defined as new gadolinium-enhancing 
T1 weighted lesions or new nonenhancing or enlarging 
T2 weighted lesions. Safety was assessed by incidence of 
treatment-emergent adverse events, physical examination, 
and laboratory measurements.
Investigators found a significant reduction in the annual-
ized relapse rate at 96 weeks in both cladribine groups (0.14 in 
3.5 mg/kg and 0.15 in 5.25 mg/kg) compared with placebo 
(0.33), with relative reductions of 57.6% and 54.5%, respec-
tively (P , 0.001). The results for the secondary endpoints 
are presented in Table 1. The HR for cladribine versus placebo 
for the time to first relapse was 0.44 for the 3.5 mg/kg group 
(95% CI: 0.34–0.58) and 0.46 for the 5.25 mg/kg group (95% 
CI: 0.36–0.6). For the time to three-month sustained change 
in EDSS score, there was a relative risk reduction of 33% 
for the 3.5 mg/kg group (HR 0.67, 95% CI: 0.48–0.93) and 
31% for the 5.25 mg/kg group (HR 0.69, 95% CI: 0.49–0.96) 
compared with placebo. Both cladribine treatment groups had 
significant reductions in magnetic resonance imaging activity 
as reported in Table 1.
Treatment-emergent adverse events are reported in 
Table 2. An adverse event was reported in 80.7% and 83.9% 
of subjects receiving cladribine 3.5 mg/kg and 5.25 mg/kg, 
respectively, compared with 73.3% of subjects receiving 
placebo. Event severity was rated with mild being an event 
or symptom easily tolerated, moderate being an event or 
symptom which interferes with or reduces the usual level of 
activity, and severe being an event or symptom which causes 
substantial impairment of functioning, reduces the usual level 
of activity, or endangers the patient’s life. The most common 
reported adverse event in the subjects receiving cladribine 
was mild or moderate lymphocytopenia. There were three 
reported cases of severe neutropenia in the cladribine 
groups, one in the 3.5 mg/kg group and two in the 5.25 mg/
kg group. Cladribine was discontinued due to adverse events 
in 3.5%, 7.9%, and 2.1% of subjects receiving 3.5 mg/kg, 
Table 1 Secondary endpoints (intention-to-treat population)
Endpoint Cladribine Cladribine
Placebo 3.5 mg/kg P value 5.25 mg/kg P value
(n = 437) (n = 433) (n = 456)
Patients relapse-free  266 345 ,0.001 360 ,0.001
Time to sustained progression of disability (months) 10.8 13.6 0.02 13.6 0.03
Time to first relapse (months) 4.6 13.4 ,0.001 13.3 ,0.001
Patients requiring rescue therapy [n (%)] 27 (6.2%) 11 (2.5%) 0.01 9 (2.0%) 0.003
Magnetic resonance imaging endpoints
Gadolinium-enhancing T1 weighted lesions (mean) 0.91 0.12 ,0.001 0.11 ,0.001
Active T2 weighted lesions (mean) 1.43 0.38 ,0.001 0.33 ,0.001
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5.25 mg/kg, and placebo, respectively. A total of 10 cases of 
neoplasm were reported in the cladribine treatment groups 
compared with no neoplasms reported in the placebo group. 
Half of the cases reported in the cladribine groups were 
benign uterine leiomyomas. The other cases were melanoma, 
pancreatic cancer, ovarian cancer, Stage 0 cervical carcinoma 
in situ, and choriocarcinoma. Because the reported neoplasms 
affected many different organ systems, investigators were 
not able to determine a causal relationship with cladribine. 
Four deaths were reported   during the study and two after 
the end of the study. The causes of death in the subjects who 
received   cladribine 3.5 mg/kg were acute myocardial infarc-
tion and metastatic pancreatic cancer. The causes of death 
in the subjects in the 5.25 mg/kg group were drowning and 
cardiopulmonary arrest secondary to exacerbation of latent 
tuberculosis infection. The authors concluded that cladribine 
may have been responsible for the reactivation of the latter 
subject’s tuberculosis. As a result, tuberculosis screening 
needs to be completed before initiation of cladribine. When 
considering reactivation of disease, it should also be noted 
that 20 patients developed herpes zoster infections. Three 
patients receiving cladribine had herpes zoster reported as 
a serious adverse event. A correlation analysis showed that 
the lowest absolute lymphocyte counts in subjects receiving 
cladribine were inversely correlated with occurrence of infec-
tion (Spearman’s correlation coefficient for both cladribine 
groups combined, -0.010, P = 0.003). For the subjects in 
the placebo group, the causes of death were suicide and 
hemorrhagic stroke.
The authors concluded that oral cladribine used as a short-
term treatment for RRMS provides a significant benefit in 
terms of rate of relapse, disability progression, and magnetic 
resonance imaging measurement of disease activity. It appears 
that oral cladribine doses of 3.5 mg/kg and 5.25 mg/kg are 
equally efficacious based upon the results of this trial.
Ongoing clinical studies
An extension study from CLARITY is further evaluating 
the safety and tolerability of oral cladribine.26 The primary 
outcome being evaluated in this study is safety determined by 
clinical laboratory testing, electrocardiography, and review 
of adverse events. Efficacy is being evaluated as a secondary 
outcome on an annual basis and cumulatively. The projected 
study completion date is September 2011.
There is currently one other ongoing randomized, double-
blind trial evaluating oral cladribine. The Phase II ONWARD 
(Cladribine Add-ON to Interferon-beta Therapy in MS 
Subjects With Active Disease) trial is evaluating the safety, 
tolerability, and effectiveness of oral cladribine when taken 
in combination with IFN β.27 Subjects have been randomized 
to receive up to four cycles of oral cladribine or matching 
placebo in combination with IFN β. The projected study 
completion date is November 2013.
Another trial evaluating oral cladribine is currently 
recruiting participants. The ORACLE MS (ORAl CLadrib-
ine in Early Multiple Sclerosis) is a Phase III randomized, 
double-blind trial assessing the efficacy and safety of oral 
cladribine compared with placebo in subjects with a first 
clinical demyelinating event at high risk of converting to 
MS.28 Subjects will be randomized to either oral cladribine 
at 1.75 mg/kg/year, 3.5 mg/kg/year, or placebo dosed once 
weekly for four weeks at the start of the cycle. The projected 
study completion date is December 2012.
Patient-specific considerations
Oral cladribine given once daily in short courses may be 
more appealing to patients than receiving subcutaneous or 
intramuscular injections indefinitely. Frequent injections can 
cause anxiety, discomfort, and inconvenience for patients.29 
The common adverse effects of oral cladribine that occurred 
in the CLARITY trial included headache, nausea, upper 
Table 2 Treatment-emergent adverse events
Adverse event  
Placebo (%)
Cladribine (%)
3.5 mg/kg 5.25 mg/
kg
Combined doses
(n = 435) (n = 430) (n = 454) (n = 884)
Most common
  Headache  75 (17.2) 104 (24.2) 94 (20.7) 198 (22.4)
  Lymphocytopenia 8 (1.8) 93 (21.6) 143 (31.5) 236 (26.7)
  Nasopharyngitis 56 (12.9) 62 (14.4) 58 (12.8) 120 (13.6)
  Upper respiratory tract infection 42 (9.7) 54 (12.6) 52 (11.5) 106 (12)
  Nausea 39 (9) 43 (10) 50 (11) 93 (10.5)
Any serious adverse event 28 (6.4) 36 (8.4) 41 (9) 77 (8.7)
  infections and infestations 7 (1.6) 10 (2.3) 13 (2.9) 23 (2.6)
  Neoplasms 0 6 (1.4) 4 (0.9) 10 (1.1)





respiratory tract infection, and lymphocytopenia. Few 
patients discontinued therapy as a result of these adverse 
effects.25 Effective, well-tolerated oral treatment for MS could 
improve long-term adherence and, therefore, help to optimize 
therapeutic outcomes.16 Long-term adverse effects must 
also be considered when evaluating cladribine and specific 
patients for its use. One important adverse effect potentially 
associated with cladribine is infertility. When administered 
intravenously to monkeys, cladribine has shown suppression 
of rapidly generating cells, eg, testicular cells. The overall 
effects of this on fertility are unknown.30
Conclusion
In determining oral cladribine’s future place in therapy, it is 
necessary to consider other emerging oral therapies. Fingolimod 
is a sphingosine-1-phosphate-receptor modulator. Recently, two 
studies evaluating oral fingolimod for the treatment of RRMS 
were published. The FREEDOMS (FTY720 Research Evaluat-
ing Effects of Daily Oral therapy in Multiple Sclerosis) study 
conducted by Kappos et al studied oral fingolimod compared 
with placebo in adult subjects.31 Oral doses of 0.5 mg and 
1.25 mg daily were studied. Statistically significant differences 
were seen with oral fingolimod compared with placebo with 
regard to annualized relapse rate and risk of disability progres-
sion over a two-year time period. For fingolimod 0.5 mg daily, 
the annualized relapse rate was 0.18. For fingolimod 1.25 mg 
daily, the annualized rate was 0.16. This is compared with an 
annualized relapse rate of 0.40 for placebo (P , 0.001 for either 
dose). Both doses of fingolimod reduced the risk of disability 
progression over a two-year period with an HR of 0.70 for 0.5 mg 
daily and 0.68 for 1.25 mg daily (P = 0.02 for both doses versus 
placebo). Oral fingolimod was also studied by Cohen et al in the 
TRANSFORMS (TRial Assessing injectable interferoN versuS 
FTY720 Oral in Relapsing-remitting Multiple Sclerosis) study.32 
In this trial, oral fingolimod, at the same doses of 0.5 mg and 
1.25 mg daily, was compared with intramuscular IFN β-1a. A 
statistically significant reduction in the annualized relapse rate 
was detected for both doses of oral fingolimod compared with 
intramuscular IFN β-1a (P , 0.001 for both doses). However, 
there was no difference in disability progression.
New therapies for the treatment of MS must demonstrate 
an improvement in the benefit-risk ratio for the current 
DMTs.33 ONWARD and ORACLE MS should provide 
additional information about oral cladribine. In further defin-
ing oral cladribine’s place in therapy for RRMS, additional 
studies will be necessary. Trials evaluating oral cladribine 
compared with IFN therapy or glatiramer would provide 
additional insight into its effectiveness. Such studies would 
also be beneficial in determining if oral cladribine should be 
considered a first-line agent or a second-line agent, such as 
natalizumab. In June 2010, Merck filed a New Drug Applica-
tion with the US Food and Drug Administration for cladribine 
tablets in the treatment of RRMS.34
In the current MS management environment, DMT is 
  limited to injectable therapies. The pharmacokinetic and phar-
macodynamic profile of cladribine has made it a theoretic option 
for short-term oral treatment. The four to six short courses of 
therapy with two years of benefit seen in the   CLARITY study, 
indicates that short-term treatment has the potential for long-
term effects. Combining the theoretic option with promising 
clinical results from the CLARITY study makes an oral treat-
ment alternative for RRMS closer to reality.
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